Xilio Therapeutics annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Xilio Therapeutics Capital Expenditures (CapEx) Growth & History (XLO)
Xilio Therapeutics's capital expenditures (capex) was $518,000 for fiscal 2025.
View full Xilio Therapeutics company overviewXilio Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $518,000 | $482,000 | +1338.89% |
| 2024 | 2024-12-31 | $36,000 | −$450,000 | −92.59% |
| 2023 | 2023-12-31 | $486,000 | −$1.4M | −73.97% |
| 2022 | 2022-12-31 | $1.9M | $767,000 | +69.73% |
| 2021 | 2021-12-31 | $1.1M | −$1.1M | −49.73% |
| 2020 | 2020-12-31 | $2.2M | — | — |
Xilio Therapeutics quarterly capital expenditures (capex)
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19,000 | −$382,000 | −95.26% |
| Q1 2026 | 2026-03-31 | $556,000 | $534,000 | +2427.27% |
| Q4 2025 | 2025-12-31 | $95,000 | $89,000 | +1483.33% |
| Q3 2025 | 2025-09-30 | $0 | −$9,000 | — |
| Q2 2025 | 2025-06-30 | $401,000 | — | — |
| Q1 2025 | 2025-03-31 | $22,000 | — | — |
| Q4 2024 | 2024-12-31 | $6,000 | $6,000 | — |
| Q3 2024 | 2024-09-30 | $9,000 | $9,000 | — |
| Q4 2023 | 2023-12-31 | $0 | −$509,000 | — |
| Q3 2023 | 2023-09-30 | $0 | −$333,000 | — |
| Q2 2023 | 2023-06-30 | $316,000 | −$455,000 | −59.01% |
| Q1 2023 | 2023-03-31 | $170,000 | −$84,000 | −33.07% |
| Q4 2022 | 2022-12-31 | $509,000 | $131,000 | +34.66% |
| Q3 2022 | 2022-09-30 | $333,000 | $219,000 | +192.11% |
| Q2 2022 | 2022-06-30 | $771,000 | $333,000 | +76.03% |
| Q1 2022 | 2022-03-31 | $254,000 | $84,000 | +49.41% |
| Q4 2021 | 2021-12-31 | $378,000 | — | — |
| Q3 2021 | 2021-09-30 | $114,000 | — | — |
| Q2 2021 | 2021-06-30 | $438,000 | — | — |
| Q1 2021 | 2021-03-31 | $170,000 | — | — |
Xilio Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Xilio Therapeutics's capital expenditures (capex) decreased from $2.2M to $518,000, a change of −$1.7M. The latest reported quarter, Q2 2026, shows $19,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xilio Therapeutics source filings ↗